Cervical cancer (CC) is one of the leading cancer causes of death in women worldwide. Nearly, all cases of CC and the majority of anogenital cancers and few cases of oral and oropharyngeal cancers are attributable to human papillomavirus (HPV). [1] The mortality-to-incidence ratio of CC is high (0.68) in India as compared to the developed countries (~0.38) most likely due to inaccessibility of healthcare resources for regular screening and treatment in India. [2] On the other hand, the lowest CC mortality rate of 0.27% in Australia emphasises the importance of regular CC screening and HPV vaccination. [3] Due to their superior sensitivity and epidemiological importance, HPV genotyping assays are being recommended for routine CC screening along with Pap test (known as cotesting). [4] [5] [6] Although several HPV types have been linked with CC, HPV 16 and 18 are two principal high-risk types responsible for more than 70% of all CC cases. [6, 7] Variety of commercial tests are available for detection of HPV DNA or mRNA. Most widely used signal amplification methods (e.g., Hybrid Capture 2 and Cervista) detect HPV DNA using an RNA DNA hybridisation probe with chemiluminescence Background: Many human papillomavirus (HPV) types are associated with cervical cancer (CC). Therefore, HPV genotyping has both clinical and epidemiological importance. HPV 16 and 18 are two principal high-risk types responsible for more than 70% of all CC cases. Although several commercial and non-commercial genotyping assays are available, there is a need for a cost-effective and sensitive genotyping method for low-and middle-income countries. Methods: The study was aimed at evaluation of loop-mediated isothermal amplification (LAMP) assay for HPV genotyping in cervical samples. A total of six primer sets for each HPV type were selected for the assay. The LAMP assay was standardised and validated with HPV control panel. Cervical biopsies were subjected to nested multiplex polymerase chain reaction (NM-PCR; as a part of routine diagnostic workup) and LAMP (HPV 16 and 18) simultaneously. Results: A total of 225 clinical samples were processed during the study period. The sensitivity of the assay was determined using the 10-fold dilutions of positive controls. Both the HPV 16-LAMP and HPV 18-LAMP assays were shown to detect as low as 10 viral copies per reaction, which is similar to that of NM-PCR. The LAMP assay had a good agreement (new cases; 92%, post-chemoradiotherapy [post-CRT]; 89.1%) with NM-PCR for the detection of both HPV 16 and 18. As compared to histology (new cases; 79.8%, post-CRT; 51.3%), LAMP had better agreement with NM-PCR for detection of HPV from post-CRT cases. Conclusions: We evaluated the LAMP assay for simultaneous detection and typing of HPV 16 and 18. The assay had good agreement with NM-PCR for detection of both HPV 16 and 18. The LAMP assay is a promising tool for HPV genotyping along with routine cervical cytology, especially in resource-constrained settings.
or fluorescence signals. However, their use is limited by high running costs and the requirement of dedicated equipment. On the other hand, specific target (DNA) amplification (e.g., polymerase chain reaction [PCR] ) is one of the most sensitive and direct methods for HPV detection and typing. [8] Loop-mediated isothermal amplification (LAMP), an alternative method for PCR under isothermal conditions, has been tried for several pathogens and proved to be a simple and cost-effective method. [9] [10] [11] Few studies have described previously the LAMP method for typing of most common high-risk HPV types. [12, 13] However, several factors including LAMP detection method (e.g., turbidity, SYBR Green I, etc.), HPV copy number and nature of target sequence can influence the sensitivity of the assay. [14] In the present study, the LAMP method was evaluated for genotyping of HPV 16 and 18 from cervical scrapings of women with clinically suspected CC and compared with nested PCR.
MethOdS

Study settings
The study was conducted at Virus Research and Diagnostic Laboratory (VRDL), Sri Venkateswara Institute of Medical Sciences (SVIMS), tertiary care university hospital, Andhra Pradesh, India. Institute's ethics committee clearance (IEC No: 353/dated 6 th January, 2014) was obtained before commencing the study.
Patients and samples
Prior written informed consent was obtained from the patients after explaining the nature of the study and its benefits/associated risk (if any). The study was aimed at evaluation of LAMP assay for HPV genotyping in cervical samples; hence, convenience-sampling method was used. All female patients who attended the Surgical Oncology outpatient department (OPD) of SVIMS hospital from 13 th June, 2014 to 30 th August, 2016 and those who satisfied the study inclusion criteria were selected for the study. Cervical biopsies were obtained by the clinician, as a routine diagnostic workup from clinically suspected women. The following inclusion criteria were used to select the patients for the study: 1. Women above 18 years of age who presented to the Surgical Oncology OPD with signs and symptoms such as foul-smelling vaginal discharge, vaginal bleeding, bleeding after sexual intercourse or any bleeding after menopause that looked suspicious of poor cervical health/CC 2. Pregnant women 3. Women receiving treatment for CC at the time of recruitment and those who were not willing to participate in the study were excluded.
Positive control panel for the study
Type-specific HPV DNA containing plasmid clones (obtained from Karolinska Institutet, Sweden) was used as a positive control. Plasmid concentration in the solution was determined by measuring the absorbance at 260 nm. The viral copy number per unit mass was calculated by assuming that 1 bp weighs about 660Da. [15] Then, the positive control stock was diluted serially to obtain desired copy number (10 7 -one copy/ µl).
Loop-mediated isothermal amplification for human papillomavirus 16 and 18
Primer selection HPV 16 and 18 primers that flank E7 and L1 regions, respectively, were selected from a published research article. [16] National Center for Biotechnology Information (NCBI) blast search was performed to verify the specificity of the primers. A total of six primer sets were selected for each HPV 16 and 18 LAMP assay: two outer primers (F3 and B3), two inner primers (forward inner primer [FIP] and backward inner primer [BIP]) and two loop primers (loop forward [LF] and loop back [LB]) as shown in Table 1 .
Amplification of target DNA
LAMP was performed in a one-step reaction in a 25 µl mixture (10X Isothermal Amplification Buffer, New , inner primers (FIP/BIP) 1.6 µM each, outer primers (F3/B3) 0.2 µM each, loop primers (LF/LB) 0.4 µM each, nuclease-free water to make up the reaction volume to 20 µl and extracted DNA template (~5 µl). Tubes were kept in a water bath prewarmed to 63°C for 60 min. To each tube, 1 µl of SYBR Green-I was added, gently mixed and observed for bright green fluorescence after short exposure to blue light. Bright green fluorescence indicates the presence of the target (HPV) or successful amplification, and absence of the target was indicated by no fluorescence. The test was standardised and validated with positive and negative controls.
Testing of clinical samples
DNA was extracted from cervical scrapings/biopsies (~25 mg) using QIAamp blood and tissue DNA mini kit (QIAGEN, Hilden, Germany) following the manufacturer's protocol for 'DNA purification from tissues'. Purified DNA was eluted in 200 µl nuclease-free water and stored at −20°C for further testing. All clinical samples that yielded adequate DNA concentration and quality (human β-globin positive) were tested by both nested multiplex PCR (NM-PCR; as a part of routine diagnostic workup) and LAMP (HPV 16 and 18) simultaneously.
NM-PCR was performed in two step reaction. In the first round, degenerative primers (outer primers) that anneals to consensus e6 and e7 gene sequences of 38 common mucosal HPV types were used. [17] In the second round, PCR HPV type-specific internal primers were designed for 15 common high-and low-risk HPV types. Internal primers were designed in such a way that they produce amplicons with different sizes. These primers were arranged in three multiplex reactions (Group 1-HPV 16, 42, 45, 56; Group 2-HPV 31, 52, 53, 58, 59; Group 3-HPV 18, 33, 6, 11, 39, 61). After second-round PCR, the amplicons were separated by 2% agarose gel electrophoresis, and HPV types were identified based on the amplicon size. All reactions were performed in 25 µl reaction mixture (2x PCR Master Mix, ThermoFisher Scientific, India) containing KCl (50 mM), trisHCl (10 mM, pH 8. 
Statistical considerations
Microsoft office excel worksheet 2013 (Microsoft office suite for Windows) was used for data compilation, sorting and outlier detection. Normality was tested using Kolmogorov-Smirnov test in MedCalc version 12.1.70 for windows. An online scientific statistical program (GraphPad, last updated July 2014) was used to quantify the interrater agreement between NM-PCR and LAMP using Kappa statistic for categorical data.
reSultS
Summary of samples processed
During the study period, 241 samples were collected from women who were eligible and consented to the study. Among these, 16 samples were excluded from the study due to the following reasons: repeat cases (2), inadequate sample quality (10) and low DNA yield and poor quality (4). After excluding 16 samples, 225 samples were included in the study. Among these, 37 cases received at least one course of radiotherapy (RT) and/or chemotherapy (the samples were collected as a part of follow-up).
Standardisation of loop-mediated isothermal amplification
Using the HPV control panel, LAMP was standardised for HPV 16 and HPV 18. Then, the assay was evaluated with clinical samples. After incubation of 60 min at 63°C in a water bath, samples were examined for the bright green fluorescence on the addition of SYBR Green I [ Figure 1 ] using in-house designed blue light transilluminator. In addition to the visual inspection, samples were run in 2% agarose gel to look for the characteristic ladder-like pattern [ Figure 2 ]. The sensitivity of the assay was determined using the 10-fold dilutions of HPV 16 and 18 positive controls. Both the HPV 16-LAMP and HPV 18-LAMP assays were shown to detect as low as al copies per reaction, which is similar to that of NM-PCR assay [ Figure 3 ]. 
diScuSSiOn
Liquid-based cytology serves as a cost-effective primary CC screening method. However, neither cytology nor histological studies provided HPV type-specific details. On the other hand, molecular methods such as hybridisation (signal amplification) assays and PCR-based target amplification assays are commonly used for both HPV detection and genotyping. HPV testing is not only sensitive but also more reliable and less dependent on human expertise than visual inspection with 5% acetic acid (VIA) or cytology. [18, 19] Few genotyping assays are approved by the US-Food and Drug Administration (FDA); they are not only expensive but also demand dedicated equipment. Several commercial genotyping assays are available in the market; however, they have not been evaluated sufficiently; hence, their reliability is a question. Worldwide, two high-risk types, i.e., HPV 16 and 18 are known to be associated with more than 80% of all CCs. [20] Keeping these things in mind, we attempted to evaluate an isothermal amplification assay for differentiation and genotyping of HPV 16 and 18.
Several preservation media are available to maintain a good quality of DNA and RNA in the specimens, which lasts for a few days to several years. Depending on the purpose either proprietary (SurePath, RNAlater, DNAgurad, PreservCyt etc. can be used) [21] or non-proprietary (paraformaldehyde, neutral buffered formalin, ethanol, PBS, etc.), medium can be used for sample collection and preservation. [22] We used ethanol as a preservative essentially for two reasons. First, the study involved the detection of a short fragment of HPV DNA, and ethanol is known to preserve DNA from endonucleases. Second, ethanol inactivates the virus present in a sample, and it is a cheap and easily available preservative. [23] In this study, only four of 204 (1.9%) samples had unacceptably low DNA yield and did not amplify internal control (human beta-globin). This could be partially but not entirely attributable to poor sample preservation.
LAMP assay was evaluated with positive control panels and clinical samples. To the best of our knowledge, this is the first study that evaluated in-house designed genotyping assay in Southern India. To increase the accuracy and power of the study, a stringent design and case selection criteria were used to select our study samples from women seeking services at SVIMS, Tirupati.
Different end-point [9] and real-time [24] detection methods are available for the detection of amplification product generated by the LAMP. [25] Among these, SYBR Green-I has relatively better sensitivity; hence, we selected this dye for end-point detection of LAMP product. Studies indicated the possibility of contamination while opening LAMP tubes for adding SYBR Green-I at the end reaction. [24, 25] However, we have followed stringent safety measures to avoid such false-positive reactions.
After amplification, the products were detected by both SYBR Green-I and agarose gel electrophoresis to confirm the test report. All samples positive by visual detection method (SyBR Green-I) were also positive by agarose gel electrophoresis. The sensitivity of LAMP for the detection of HPV 16 and 18 was 10 copies per reaction [ Figure 3 ]. The results are in concordance with the sensitivity of HPV-LAMP assay reported by Lue L et. al., i.e., 100 copies for HPV16 & 10 copies for HPV18. [16] Majority of FDA-approved assays reported different lower detection limits range from 50 copies to 5,000 copies per reaction. [26, 27] The present LAMP assay showed a lower detection limit of 10 copies per reaction is comparable with these assays.
All cervical samples (new and post-CRT cases) were subjected to the LAMP (HPV 16 and 18 ) and NM-PCR. All samples tested positive for HPV 18 by the LAMP were also positive by NM-PCR. Whereas, seven (new cases) and three (post-CRT cases) samples positive by HPV 16 LAMP tested negative for HPV 16 by NM-PCR. As compared to the LAMP, NMPCR could detect more positives. LAMP assay detected HPV DNA in 23 of 37 (62.1%) post-CRT cases, whereas histology was positive in only 16 cases (43.2%) suggesting the superior sensitivity of LAMP over histology to predict post-CRT recurrence or poor treatment outcome. HPV 16 LAMP could detect seven additional positive may be explained due to the presence of PCR inhibitors in the sample; PCR is more susceptible to inhibitors as compared to a LAMP. [28] In contrast, NM-PCR could detect HPV 16 in 20 additional samples in which HPV 16 LAMP was negative. The discordance of results could be due to the presence of low viral copies in the sample. The sensitivity of NM-PCR for HPV 16 was determined as <10 copies per tube, and moreover, due to the nested PCR design, NM-PCR remained more sensitive than the LAMP assay.
After addition of SYBR Green-I, the tubes need to be exposed briefly to ultraviolet (UV) or blue light to detect fluorescence. Exposure to UV light is harmful to skin and eyes as well. Most importantly, commercially available UV or blue light transilluminators are relatively expensive. To make it feasible even in resource-limited settings, we designed a blue light transilluminator, which works on 12v DC (battery) or AC with 12v DC adaptor, suitable for rural areas and field studies. Blue light-emitting diode (LED) was the light source for the transilluminator. These LEDs are not expensive, easily available and have a long life expectancy (generally 50,000 h). Each tube was observed under standard gel documentation system (AlphaImager, Protein Simple, California, USA) and the in-house designed blue light transilluminator. As LAMP assay generates a tremendous number of amplicons in less than an hour, both instruments were able to differentiate positive and negative reactions clearly. The principle of detection is essentially the same for both the instruments except camera attachment; the in-house blue light transilluminator would be useful for routine agarose gels stained with SYBR green-I or SYBR safe. However, we did not evaluate the efficiency of this transilluminator for visualisation of PCR amplicons in agarose gel.
Overall, LAMP assay had good agreement with NM-PCR (92.0%, [κ = 0.83; 95% confidence interval = 0.75, 0.91]). Moreover, no false-positive reactions were observed with the LAMP because all seven HPV 16-LAMP+ve/NM-PCR−ve sample had histological evidence of invasive CC. Since LAMP is cost-effective and relatively sensitive as compared to NM-PCR, it is a promising technique, useful for parallel testing of cervical samples along with liquid-based cytology for VIA in resource-poor settings where hybridisation tests or PCR based tests are not feasible. As the LAMP assay requires only simple water bath/heating block and does not require a technical expert for interpretation of the results (based on color change), it can serve as an ideal HPV-detection method for field studies at a community level.
Limitations of the study
First of all, the study included only two HPV types for type-specific detection. Although there are several high-risk HPV types associated with CC, all HPV could not be detected by the LAMP assay. As the number of LAMP reactions increases per sample, testing cost also increases; therefore, we wanted to include only the most predominant HPV types (HPV 16 and 18). The LAMP assay did not compare with any other FDA-approved assays, but the sensitivity of different hybridisation assays ranges from 50 copies to 5,000 copies per reaction. However, the sensitivity of the LAMP assay was determined as 10 copies per reaction which was at par with aforementioned assays.
cOncluSiOnS
We validated the LAMP assay for the detection of the two most common HPV types. This assay had good sensitivity (10copies/reaction) which is in agreement with most of the standard HPV genotyping assays as well as the in-house NM-PCR. Most importantly, the estimated cost per sample (HPV 16 and 18 LAMP) was less than five USD, and it does not require expensive or any dedicated equipment. Therefore, this assay is suitable for routine HPV testing and post-therapy follow-up purposes in resource-poor settings with comparable sensitivity to FDA-approved standard typing assays.
